Pfizer teams up with Insilico to mine data for drug targets by Nick Paul Taylor Thursday, January 16, 2020 The partners will use Insilico’s technology to identify real-world evidence for drug targets in multiple therapeutic areas.
Concerto HealthAI unveils $150M raise, 2 pharma collaborations by Conor Hale Wednesday, January 15, 2020 Concerto HealthAI unveiled a steady drum beat of announcements at this year’s J.P. Morgan Healthcare Conference, including a $150 million raise.
JPM Tuesday: Pfizer's pipeline, 2020's bolt-on deals by Ben Adams Wednesday, January 15, 2020 The second day of the J.P. Morgan Healthcare Conference again saw no major M&A deals but did see some of the bigger pharma companies present.
Biogen pays Pfizer $75M for early-phase Alzheimer's drug by Nick Paul Taylor Monday, January 13, 2020 The CK1 inhibitor passed tests in healthy volunteers at Pfizer before getting derailed by the Big Pharma’s retreat from neuroscience R&D in 2018.
Axsome picks up Pfizer's phase 3 fibromyalgia castoff by Nick Paul Taylor Monday, January 13, 2020 The deal gives Axsome the chance to resurrect a drug that beat placebo in phase 3 but nonetheless fell by the wayside at Pfizer.
Pfizer's Read picks up position at new firm—Chutes & Ladders by Kyle Blankenship Friday, January 10, 2020 Pfizer ex-CEO Read picks up job at The Carlyle Group; AMAG dumps CEO Heiden; ex-Lilly chief Conterno joins team at Fibrogen.
Pfizer taps Effector to develop anti-cancer eIF4E inhibitors by Nick Paul Taylor Thursday, January 9, 2020 Effector is set to receive $15 million upfront to work on drugs against the oncogenic driver, which is found downstream of the RAS and PI3K pathways.
Pfizer's Read to take board seat at Viatris—Chutes & Ladders by Kyle Blankenship Friday, December 20, 2019 Pfizer Chairman Read to take Viatris board seat; Bristol's Biondi bolts; Ipsen CEO Meek takes over new company.
Is there a future for pharma in neuro? by Nick Paul Taylor Friday, December 20, 2019 The retreat of big biopharma from neuroscience R&D continued apace in 2019, with Amgen axing its neuroscience unit and Eli Lilly shuttering a U.K. fac
10. Vyndaqel by Amirah Al Idrus Alnylam and Ionis may have been first and second to market with a drug for the rare disease transthyretin-mediated amyloidosis, but Pfizer’s Vyndaqel may yet carve itself a niche.
